- Healthcare and genetics company Benchmark said challenging conditions in the global shrimp, Mediterranean seabass and bream markets had continued to hurt sales volumes in advanced nutrition.

The company also said its expectations for the revenue and profit mix for the full year had changed as it sought to continue implementing operational and structural efficiencies, including key commercial licensing deals for its non-core animal vaccines.

These deals, if completed this financial year, were expected to substantially offset the current headwinds. But there was a risk to the delivery of these deals within the current financial year, the company added.

'Notwithstanding these short-term challenges, the Board believes that the Company is well positioned in its markets and the opportunities for its existing products and those coming from its pipeline are strong,' Benchmark said.

Story provided by